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AbstrAct
Objective
To determine the effectiveness of management 
strategies for uninvestigated dyspepsia.
Design
Systematic review and network meta-analysis.
Data sOurces
Medline, Embase, Embase Classic, the Cochrane 
Central Register of Controlled Trials, and clinicaltrials.
gov from inception to September 2019, with no 
language restrictions. Conference proceedings 
between 2001 and 2019.
eligibility criteria fOr selecting stuDies
Randomised controlled trials that assessed 
the effectiveness of management strategies for 
uninvestigated dyspepsia in adult participants 
(age ≥18 years). Strategies of interest were prompt 
endoscopy; test for Helicobacter pylori and perform 
endoscopy in participants who test positive; test for 
H pylori and eradication treatment in those who test 
positive (“test and treat”); empirical acid suppression; 
or symptom based management. Trials reported 
dichotomous assessment of symptom status at final 
follow-up (≥12 months).
results
The review identified 15 eligible randomised 
controlled trials that comprised 6162 adult 
participants. Data were pooled using a random 
effects model. Strategies were ranked according to P 
score, which is the mean extent of certainty that one 
management strategy is better than another, averaged 
over all competing strategies. “Test and treat” ranked 
first (relative risk of remaining symptomatic 0.89, 
95% confidence interval 0.78 to 1.02, P score 0.79) 
and prompt endoscopy ranked second, but performed 
similarly (0.90, 0.80 to 1.02, P score 0.71). However, 
no strategy was significantly less effective than “test 
and treat.” Participants assigned to “test and treat” 
were significantly less likely to receive endoscopy 
(relative risk v prompt endoscopy 0.23, 95% 
confidence interval 0.17 to 0.31, P score 0.98) than all 
other strategies, except symptom based management 
(relative risk v symptom based management 0.60, 
0.30 to 1.18). Dissatisfaction with management was 
significantly lower with prompt endoscopy (P score 
0.95) than with “test and treat” (relative risk v “test 
and treat” 0.67, 0.46 to 0.98), and empirical acid 
suppression (relative risk v empirical acid suppression 
0.58, 0.37 to 0.91). Upper gastrointestinal cancer 
rates were low in all trials. Results remained stable 
in sensitivity analyses, with minimal inconsistencies 
between direct and indirect results. Risk of bias of 
individual trials was high; blinding was not possible 
because of the pragmatic trial design.
cOnclusiOns
“Test and treat” was ranked first, although it 
performed similarly to prompt endoscopy and was 
not superior to any of the other strategies. “Test 
and treat” led to fewer endoscopies than all other 
approaches, except symptom based management. 
However, participants showed a preference for 
prompt endoscopy as a management strategy for their 
symptoms.
systematic review registratiOn
PROSPERO registration number CRD42019132528.
Introduction
Dyspepsia is a common condition that could involve 
a variety of upper gastrointestinal symptoms, but the 
main symptom is upper abdominal pain or discomfort.1 
At some point in their lives, one in five adults report 
epigastric pain, early satiety, postprandial distress, 
and other associated upper gastrointestinal symptoms, 
such as heartburn, regurgitation, or nausea. Although 
dyspepsia is not associated with higher mortality risk,2 3 
the condition is chronic in many people4 and follows 
a fluctuating course.5-7 Dyspepsia has a substantial 
impact on patients’ quality of life,8 and is associated 
with more time off work and lower productivity at 
work, and greater medical and prescription drug costs 
each year.9 10 The financial implications for society as 
a whole are huge.11
Approximately 40% of people with dyspepsia 
symptoms will consult a primary care physician.12 
The physician has to make a decision about how 
best to manage the individual patient. Patients with 
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WhAt Is AlreAdy knoWn on thIs topIc
Dyspepsia is a highly prevalent and costly condition
Many management approaches have been compared in pragmatic randomised 
controlled trials, and summarised in individual patient data meta-analyses, but 
there is equipoise between strategies
Guidelines disagree about which approach should be used for the initial 
management of uninvestigated dyspepsia
WhAt thIs study Adds
This network meta-analysis found “test and treat” was ranked first, although 
it performed similarly to prompt endoscopy and was not superior to any of the 
other strategies
“Test and treat” led to fewer endoscopies than all other strategies except 
symptom based management
Participants showed a preference for prompt endoscopy as a management 
strategy for their symptoms
Wider application of a “test and treat” strategy for dyspepsia at the primary 
care level, which is recommended in recent national guidelines, should be 
encouraged
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uninvestigated dyspepsia and alarm features, such 
as dysphagia, weight loss, or anaemia, or those older 
than a certain age threshold, require urgent endoscopy. 
However, the management of uninvestigated dyspepsia 
in the absence of alarm features represents a classic 
medical decision making problem because several 
strategies exist. These strategies include prompt 
endoscopy for all patients; test for Helicobacter pylori 
and perform endoscopy in those who test positive (“test 
and scope”); test for H pylori and eradication treatment 
in those who test positive (“test and treat”); empirical 
acid suppression for all patients; or symptom based 
management according to guideline recommendations 
or the physician’s usual practice.
The effectiveness of these different strategies has 
been studied in numerous pragmatic randomised 
controlled trials.13-17 However, there is equipoise 
among various strategies and uncertainty as to which 
strategy is best to use first line. Trial based meta-
analyses, and even individual patient data meta-
analyses, have been unable to resolve this uncertainty 
completely. Although prompt endoscopy is expensive, 
it appears to be superior to empirical acid suppression 
or symptom based management when comparing the 
effect on symptoms in some patients,15 18 and was 
superior to “test and treat” in an individual patient 
data meta-analysis.19 However, it is unlikely to be 
cost effective,19 and therefore is not recommended 
as first line treatment in management guidelines for 
uninvestigated dyspepsia.20 21 Another individual 
patient data meta-analysis of “test and treat” versus 
empirical acid suppression showed no difference in 
either costs or effects between the two strategies.22 As 
a result, guidelines disagree about which approach 
should be used for the initial management of un-
investigated dyspepsia (table 1).20-23
Network meta-analysis might be able to resolve 
some of this uncertainty because the methods used 
allow indirect and direct comparisons across different 
randomised controlled trials, which increases the 
number of participants’ data available for analysis. 
Additionally, network meta-analysis allows a credible 
ranking system to be developed that shows the 
effectiveness of different management strategies, even 
in the absence of trials making direct comparisons, 
which can help to inform clinical decision making. 
Therefore, we conducted a network meta-analysis 
of all available randomised controlled trials that 
have compared five management strategies for un-
investigated dyspepsia.
Methods
search strategy and study selection
We searched Medline (from 1947 to September 2019), 
Embase, Embase Classic (from 1947 to September 
2019), and the Cochrane Central Register of Controlled 
Trials to identify potential studies. In addition, we 
searched national guidelines for the management of 
dyspepsia, clinicaltrials.gov for unpublished trials, 
and supplementary data for potentially eligible studies 
(all up to September 2019). Conference proceedings 
(Digestive Disease Week, American College of Gastro-
enterology, United European Gastroenterology Week, 
and the Asian Pacific Digestive Week) between 2001 
and 2019 were hand searched to identify studies 
published only in abstract form. Finally, we performed 
a recursive search by using the bibliographies of all 
obtained articles.
Eligible randomised controlled trials examined 
the effect of various management strategies for un-
investigated dyspepsia (prompt endoscopy, “test and 
treat,” “test and scope,” empirical acid suppression, 
or symptom based management) in adult participants 
(age ≥18 years). The definition of dyspepsia was broad 
and included any upper gastrointestinal symptoms 
referable to the gastroduodenum. We only considered 
randomised controlled trials to be eligible when they 
examined the effectiveness of one of the strategies of 
interest and compared it with at least one of the other 
strategies. Because dyspepsia is a chronic fluctuating 
condition,4 a minimum follow-up of 12 months was 
required. We extracted all endpoints at the final 
point of follow-up to ensure as much homogeneity as 
possible among individual trial results, and to avoid 
overestimating the effectiveness of one management 
strategy relative to another. Studies had to report a 
dichotomous assessment of symptom status at the 
final point of follow-up (box 1). The study protocol was 
published on the PROSPERO international prospective 
register of systematic reviews (registration number 
CRD42019132528). 
Two investigators (LHE and ACF) conducted the 
literature search independently from each other. 
We report the search strategy in the supplementary 
materials. There were no language restrictions. 
Two investigators (LHE and ACF) evaluated all ab-
stracts identified by the search for eligibility, again 
independently from each other. We obtained all 
potentially relevant papers and evaluated them in more 
detail by using predesigned forms to assess eligibility 
independently, according to the predefined criteria. 
We translated foreign language papers if required. 
Disagreements between investigators were resolved by 
discussion.
Outcome assessment
We assessed the effectiveness of all five management 
strategies of uninvestigated dyspepsia by comparing 
the probability of being symptomatic at the final point 
of follow-up. Additionally, because individual trials 
reported several other secondary endpoints, we were 
able to assess the likelihood of participants receiving 
endoscopy in each treatment arm, and dissatisfaction 
with management. Finally, we recorded rates of upper 
gastrointestinal cancer detection.
Data extraction
Two investigators (LHE and ACF) extracted all data 
independently onto a Microsoft Excel spreadsheet 
(XP professional edition) as dichotomous outcomes 
(symptomatic or asymptomatic at final point of 
follow-up). For all included studies, we also extracted 
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the following data for each trial, when available: 
country of origin, setting, duration of follow-up, age 
range of included participants, proportion of female 
participants, proportion of participants with H pylori 
infection, and exact management strategy used. Data 
were extracted as intention to treat analyses, with 
dropouts assumed to be treatment failures (that is, 
symptomatic at final point of follow-up), by using 
the total number of participants randomised to each 
treatment arm as the denominator, wherever trial 
reporting allowed. Given the duration of follow-up 
in individual trials, we also performed a sensitivity 
analysis by using a per protocol analysis and including 
all participants with reported evaluable data at the 
final point of follow-up.
Quality assessment and risk of bias
This assessment was performed at the study level by 
two investigators (LHE and ACF) independently by 
using the Cochrane risk of bias tool.24 Disagreements 
were resolved by discussion. We recorded the methods 
used to generate the randomisation schedule and 
conceal treatment allocation. We also noted whether 
blinding was implemented for participants, personnel, 
and outcomes assessment, whether there was evidence 
of incomplete outcomes data, and whether there was 
evidence of selective reporting of outcomes.
Data synthesis and statistical analysis
We performed a network meta-analysis by using the 
frequentist model with the statistical package “netmeta” 
(version 0.9-0, https://cran.r-project.org/web/packages/
netmeta/index.html) in R (version 3.4.2). Firstly, we 
performed a pairwise meta-analysis of the raw data 
(supplementary figs 1-3) to convert them from contrast 
based format to long format, and to generate the 
treatment effect and standard error of the treatment effect 
for each pairwise treatment comparison. Subsequently, 
we used these data to conduct a network meta-analysis 
by using netmeta, which assumes a common τ2 for all 
pairwise comparisons. The estimate of τ2 is based on the 
generalised DerSimonian-Laird method.25 Uncertainty 
is not accounted for fully in this model because the 
distribution of parameters such as the between study 
variance is not assumed. In multiarm studies, all 
pairwise comparisons are considered, not only those 
with a common comparator, but are downweighted.25 
We reported the network meta-analysis according to 
the PRISMA (preferred reporting items for systematic 
reviews and meta-analyses) extension statement for 
network meta-analyses.26 Network meta-analysis results 
usually give a more precise estimate compared with 
results from standard, pairwise analyses,27 28 and 
can rank management strategies to inform clinical 
decisions.29
We examined the symmetry and geometry of the 
evidence by producing a network plot with node and 
connection size corresponding to the number of study 
participants and number of studies, respectively. We 
produced comparison adjusted funnel plots to explore 
publication bias or other small study effects for all 
available comparisons by using Stata (version 14, 
Stata, College Station, TX). This is a scatterplot of effect 
size versus precision, measured through the inverse of 
the standard error. Symmetry around the effect estimate 
line indicates the absence of publication bias, or small 
study effects.30 We produced a pooled relative risk with 
95% confidence interval to summarise the effectiveness 
of each management strategy tested by using a random 
effects model as a conservative estimate. We used the 
relative risk of remaining symptomatic at the final point 
of follow-up; when the relative risk is less than one and 
the 95% confidence interval does not cross one, there 
is a substantial benefit of one management strategy 
over another. Because there were direct comparisons 
between all of the management strategies, we were 
able to perform consistency modelling to check the 
agreement between direct and indirect evidence.31
Many meta-analyses use the I2 statistic to measure 
heterogeneity, which ranges between 0% and 100%.32 
This statistic is easy to interpret and does not vary 
with the number of studies. However, the I2 value 
can increase with the number of patients included 
in the meta-analysis.33 Therefore, we assessed global 
statistical heterogeneity across all comparisons using 
the τ2 measure from the netmeta statistical package. 
table 1 | recommendations from previous guidelines on various initial management strategies for uninvestigated dyspepsia
guideline when to endoscope when to use “test and treat” when to use empirical acid suppression therapy
ACG and CAG 2017 
(North America)20
First line in people aged ≥60 years; strength of 
recommendation: conditional; level of evidence: 
very low. First line in those aged ≥60 years with 
alarm features; strength of recommendation: 
conditional; level of evidence: moderate
First line in those aged <60 years; likely to be 
cost effective even with low rates of infection 
because of reduction in gastric cancer rates in 
infected individuals; strength of recommenda-
tion: strong; level of evidence: high
First line in those aged <60 years if H pylori neg-
ative, or in those who remain symptomatic after 
eradication therapy; use empirical proton pump 
inhibitor treatment at standard dose; strength of 
recommendation: strong; level of evidence: high
NICE 2014 (England 
and Wales)21
First line in people aged ≥55 years with weight 
loss and dyspepsia; consider when Helicobacter 
pylori eradication or empirical acid suppression 
fails; strength of recommendation: “offer”*; level 
of evidence: high
First line in people with dyspepsia; if this fails 
use empirical acid suppression with full dose 
proton pump inhibitor; strength of recommenda-
tion: “offer”*; level of evidence: high
First line in people with dyspepsia; use empirical 
full dose proton pump inhibitor treatment for four 
weeks; if this fails use “test and treat”; strength 
of recommendation: “offer”*; level of evidence: high
Asia-Pacific Working 
Party 199823
First line in people aged 35-55 years (depend-
ing on risk of gastric cancer in region) or alarm 
features (any age); if H pylori eradication or em-
pirical acid suppression fails consider in younger 
patients; strength of recommendation: not stated; 
level of evidence: not reported
Consider if empirical acid suppression fails; 
in areas with high prevalence of H pylori this 
strategy is unlikely to be beneficial; strength of 
recommendation: not stated; level of evidence: 
not reported
First line for young patients with no alarm features; 
either proton pump inhibitor or histamine 2 recep-
tor antagonists at standard dose for two to four 
weeks; strength of recommendation: not stated; 
level of evidence: not reported
ACG=American College of Gastroenterology; CAG=Canadian Association of Gastroenterology; NICE=National Institute for Health and Care Excellence.
*“Offer,” for most patients, an intervention will do more good than harm.
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Estimates of τ2 of approximately 0.04, 0.16, and 
0.36 are considered to represent a low, moderate, 
and high degree of heterogeneity, respectively.34 
We assessed inconsistency in the network analysis 
by comparing direct and indirect evidence, when 
available, by producing a network heat plot.31 35 These 
plots have grey squares, which represent the size of 
the contribution of the direct estimate in columns, 
compared with the network estimate in rows.35 
The coloured squares around these represent the 
degree of inconsistency, with red squares indicating 
“hotspots” of inconsistency. We planned to remove 
studies that introduced any red “hotspots” and to 
repeat the analyses to investigate sources of potential 
inconsistency. We also applied the χ2 test of the Q 
statistic to test for inconsistency, under the assumption 
of a full design by treatment interaction random effects 
model.35 36 Finally, we tested for local inconsistency by 
splitting the network estimates into the contribution 
of direct and indirect evidence, and looking for any 
statistically significant differences.
We ranked management strategies according to their 
P score, which is between 0 and 1. P scores are based 
solely on the point estimates and standard errors of 
the network estimates, and measure the mean extent 
of certainty that one management strategy is better 
than another, averaged over all competing strategies.37 
Higher scores indicate a greater probability of the 
strategy being ranked as best,37 but the magnitude 
of the P score should be considered in addition to 
the rank. Because the mean P score is always 0.5, 
individual strategies that cluster around this score are 
likely to be of similar effectiveness. However, when 
interpreting the results, it is also important to take 
into account the relative risk and corresponding 95% 
confidence interval for each comparison, rather than 
relying on rankings alone.38 In our primary analysis, 
we pooled data for the risk of being symptomatic at the 
final point of follow-up in each study for all included 
randomised controlled trials by using an intention 
to treat analysis. We also performed a per protocol 
analysis, and conducted analyses of the likelihood of 
receiving endoscopy, dissatisfaction with management 
among participants, and rates of upper gastrointestinal 
cancer.
We compared the relative effectiveness of all five 
management strategies using the “NetMetaXL” 
tool running in WinBUGS (version 1.4, Imperial 
College and MRC, London),39 which uses Bayesian 
methods. We used a random effects model with vague 
(uninformative) priors to achieve a conservative 
estimate of relative efficacy. Strategies were ranked 
according to their surface under the cumulative ranking 
curve value, which is comparable to the P score used in 
the frequentist model of our primary analyses.37 There 
were no differences in rankings among approaches, 
and therefore, for clarity, we only report the frequentist 
model in this paper, which is consistent with our 
approach for reporting previously published network 
meta-analyses.40-44
Because one of the studies was a cluster randomised 
trial,45 with patients assigned to treatment strategy 
by primary care practice, rather than randomised 
individually, we used the cluster size and the intra 
cluster correlation coefficient to reduce the size of 
the trial to its “effective sample size,” which was 440 
participants (233 “test and treat” and 207 empirical 
acid suppression), before any data pooling was carried 
out.46 If clustering is ignored, a “unit of analysis error” 
can occur,47 which will overestimate the effect of the 
intervention in the study, and also mean the study’s 
weight in the meta-analysis is artificially high.
Patient and public involvement
This was a network meta-analysis of previously 
published randomised controlled trials. It was not 
possible for us to involve patients or the public in 
defining the research question, the design, or the 
evaluation and discussion of our work. We will 
disseminate our findings in lay terms through the 
national charity for people living with digestive 
diseases, “Guts UK.”
results
The search strategy generated 8781 citations, 59 of 
which we retrieved for further assessment because 
they appeared to be relevant (supplementary fig 4). 
Of these, 44 were excluded for various reasons, which 
left 15 eligible randomised controlled trials that 
comprised 6162 participants. Fourteen trials were 
fully published,13-18 45 48-54 and data from another trial 
were available from a previous individual patient data 
meta-analysis conducted by our group.19 Agreement 
between investigators for trial eligibility was excellent 
(κ statistic=0.91). Supplementary table 1 reports risk 
of bias items for all included trials. Because the trials 
were all pragmatic, with blinding of participants 
impossible because of the differences in the strategies 
used, none was at low risk of bias.
Table 2 presents detailed characteristics of individual 
randomised controlled trials and the comparisons 
made. Six randomised controlled trials compared 
prompt endoscopy with “test and treat”17 19 48-51; 
three “test and treat” with empirical acid sup-
pression14 45 52; two prompt endoscopy with empirical 
acid suppression13 53; one prompt endoscopy with 
symptom based management15; one “test and scope” 
with symptom based management16; one prompt 
endoscopy with empirical acid suppression or symptom 
based management54; and one prompt endoscopy with 
“test and scope,” “test and treat,” or empirical acid 
box 1: eligibility criteria
•	Randomised controlled trials
•	Adults (aged ≥18 years)
•	Uninvestigated dyspepsia, before first investigation
•	Compared strategy of interest with at least one other strategy: prompt endoscopy, 
“test and scope,” “test and treat,” empirical acid suppression, or symptom based 
management
•	Minimum follow-up duration of 12 months
•	Dichotomous assessment of dyspeptic symptoms at minimum of 12 months
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table 2 | characteristics of randomised controlled trials of management strategies for uninvestigated dyspepsia
study
country, setting, and 
duration of follow-up
characteristics of included 
participants no of participants in each trial arm and management strategies used
Bytzer 199413 Denmark, primary care, 
12 months
414 participants ≥18 years, mean  
age 44 years, 238 (57.5%) female
208 participants prompt endoscopy with medical treatment according to endoscopic findings; 
206 participants empirical acid suppression using ranitidine 150 mg twice daily for four weeks
Heaney 199948 Northern Ireland,  
secondary care,*  
12 months
104 participants ≥18-45 years, 
mean age 32 years, 45 (43.3%) 
female, 104 (100%) Helicobacter 
pylori positive
52 participants prompt endoscopy with medical treatment according to endoscopic findings; 
52 participants “test and treat” by carbon 13 urea breath test, with those testing positive receiving 
eradication treatment with one week of omeprazole 20 mg twice daily, clarithromycin 250 mg twice 
daily, and tinidazole 500 mg twice daily
Delaney 200015 England, primary care, 
18 months
442 participants ≥50 years, mean 
age 65 years, 222 (50.7%) female
256 participants prompt endoscopy with medical treatment according to endoscopic findings; 
186 participants symptom based management according to the primary care physician’s preferred 
strategy
Lassen 200049 Denmark, secondary 
care,* 12 months
500 participants ≥18 years, mean 
age 46 years, 270 (54.0%) female, 
141 (28.2%) H pylori positive
250 participants prompt endoscopy with medical treatment according to endoscopic findings; 
250 participants “test and treat” by carbon 13 urea breath test, with those testing positive  
receiving eradication treatment with two weeks of lansoprazole 30 mg twice daily, metronidazole 
500 mg three times daily, and amoxicillin 1 g twice daily; those testing negative received  
reassurance and lifestyle advice
Delaney 200116 England, primary care, 
18 months
478 participants ≥18-49 years, 
mean age 37 years, 204 (42.9%) 
female, 112 (40.3%) of 278 in 
“test and scope” arm H pylori 
positive
285 participants “test and scope” by serology, with endoscopy for H pylori positive participants and 
medical treatment according to endoscopic findings; those testing negative received empirical acid 
suppression; 
193 participants symptom based management according to the primary care physician’s preferred 
strategy
Lewin van den 
Broek 200154
The Netherlands,  
primary care,  
12 months
265 participants ≥18 years, mean 
age 43.5 years, 113 (45.9%) of 
246 with data female
86 participants prompt endoscopy with medical treatment according to endoscopic findings; 
89 participants empirical acid suppression using omeprazole 20 mg once daily for up to eight weeks; 
90 participants symptom based management according to national primary care guidelines
McColl 200217 Scotland, secondary 
care,* 12 months
708 participants ≥18-55 years, 
mean age 36 years, 331 (46.8%) 
female, 352 (49.7%) H pylori 
positive
352 participants prompt endoscopy; also tested for H pylori by carbon 14 urea breath test, with 
those testing positive receiving eradication treatment as described below; 
356 participants “test and treat” by carbon 14 urea breath test, with those testing positive receiv-
ing eradication treatment with one week of omeprazole 20 mg twice daily, clarithromycin 250 mg 
three times daily, and amoxicillin 500 mg or metronidazole 400 mg three times daily; those testing 
negative received reassurance
Arents 200350 The Netherlands,  
primary care,  
12 months
270 participants ≥18 years, mean 
age 44 years, 141 (52.2%) female, 
102 (37.8%) H pylori positive
129 participants prompt endoscopy with medical treatment according to endoscopic findings; 
also tested for H pylori by serology, with those testing positive receiving eradication treatment, as 
described below; 
141 participants “test and treat” by serology, with those testing positive receiving eradication 
treatment with one week of lansoprazole 30 mg twice daily, amoxicillin 1 g twice daily, and  
metronidazole or clarithromycin 500 mg twice daily; those testing negative received cisapride 20 
mg twice daily for four weeks
Manes 200352 Italy, secondary care,* 
12 months
219 participants ≥18-45 years, 
mean age 38.5 years, 99 (45.2%) 
female, 67 (60.9%) of 110 in “test 
and treat” arm H pylori positive
110 participants “test and treat” by carbon 13 urea breath test, with those testing positive  
receiving eradication treatment with one week of omeprazole 20 mg twice daily, clarithromycin  
500 mg twice daily, and tinidazole 500 mg twice daily; those testing negative received omeprazole 
20 mg once daily for four weeks; 
109 participants empirical acid suppression using omeprazole 20 mg once daily for four weeks
Jarbol 200645 Denmark, primary care, 
12 months
472 participants ≥18 years, mean 
age 45.4 years, 272 (57.6%) 
female, 60 (24.0%) of 250 in “test 
and treat” arm H pylori positive
250 participants “test and treat” by carbon 13 urea breath test, with those testing positive  
receiving eradication treatment with one week of esomeprazole 20 mg twice daily, clarithromycin 
500 mg twice daily, and amoxicillin 1 g twice daily; those testing negative received no treatment; 
222 participants empirical acid suppression using esomeprazole 20 mg twice daily for one week
Kjeldsen 200753 Denmark, primary care, 
12 months
368 participants ≥18 years, mean 
age 48 years, 202 (54.9%) female
184 participants prompt endoscopy with medical treatment according to endoscopic findings; 
184 participants empirical acid suppression using omeprazole 40 mg once daily for two weeks
Delaney 200814 England, primary care, 
12 months
699 participants ≥18-65 years, 
mean age 41 years, 355 (50.8%) 
female, 100 (29.2%) of 343 
in “test and treat” arm H pylori 
positive
343 participants “test and treat” by carbon 13 urea breath test, with those testing positive  
receiving eradication treatment with one week of omeprazole 20 mg once daily, clarithromycin 250 
mg twice daily, and metronidazole 400 mg twice daily; those testing negative received omeprazole 
20 mg once daily for four weeks; 
356 participants empirical acid suppression using omeprazole 20 mg once daily for four weeks
Mahadeva 200851 Malaysia, secondary 
care,* 12 months
432 participants ≥18-45 years, 
mean age 30.5 years, 234 (54.2%) 
female, 141 (32.6%) H pylori 
positive
210 participants prompt endoscopy with medical treatment according to endoscopic findings; also 
tested for H pylori by rapid urease test, with those testing positive receiving eradication treatment, 
as described below; 
222 participants “test and treat” by carbon 13 urea breath test, with those testing positive  
receiving eradication treatment with one week of pantoprazole 40 mg twice daily, clarithromycin 
500 mg twice daily, and amoxicillin 1 g twice daily; those testing negative received reassurance and 
symptom based treatment
Duggan 200918 England, primary care, 
12 months
762 participants ≥18-70 years, 
mean age 42 years, 351 (46.1%) 
female, 277 (36.4%) H pylori 
positive
187 participants prompt endoscopy with medical treatment according to endoscopic findings; 
199 participants “test and scope” by serology, with endoscopy for H pylori positive participants and 
medical treatment according to endoscopic findings; those testing negative received lansoprazole 
30 mg once daily for four weeks; 
198 participants “test and treat” by serology, with those testing positive receiving eradication 
treatment with one week of omeprazole 20 mg twice daily, clarithromycin 250 mg twice daily, and 
metronidazole 400 mg twice daily; those testing negative received lansoprazole 30 mg once daily 
for four weeks; 
178 participants empirical acid suppression using lansoprazole 30 mg once daily for four weeks
Myres (unpub-
lished)†
Wales, primary care,  
12 months
61 participants ≥18-45 years, 
mean age 34 years, 33 (54.1%)  
female, 61 (100%) H pylori 
positive
28 participants prompt endoscopy with medical treatment according to endoscopic findings; 
33 participants “test and treat” by serology, with those testing positive receiving eradication  
treatment according to the primary care physician’s preferred strategy for treatment of H pylori
*Participants recruited in secondary care at first referral from primary care.
†Data available in Ford 2005.19
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suppression.18 Direct evidence was therefore available 
for nine of the 10 possible comparisons. All trials were 
of 12 months’ duration, with the exception of two 
randomised controlled trials in which the final point of 
follow-up was 18 months.15 16
effectiveness
Intention to treat analysis
All 15 randomised controlled trials provided dicho-
tomous data for likelihood of remaining symptomatic 
at the final point of follow-up.13-19 45 48-54 In these 15 
trials, 1942 participants were randomised to prompt 
endoscopy, 484 to “test and scope,” 1938 to “test and 
treat,” 1329 to empirical acid suppression, and 469 
to symptom based management. Figure 1 presents the 
network plot. When data were pooled, there was little 
observed heterogeneity (τ2=0.007), and no evidence 
of publication bias or other small study effects 
(supplementary fig 5). Of the five strategies, “test 
and treat” was ranked first (relative risk of remaining 
symptomatic 0.89, 95% confidence interval 0.78 to 
1.02, P score 0.79; fig 2). The network heat plot had 
no red “hotspots” of inconsistency (supplementary fig 
6), and there was no evidence of inconsistency under 
the full design by treatment interaction model after 
applying the χ2 test of the Q statistic (1.91, P=0.93). 
The netsplit analysis did not identify any significant 
differences between the direct and indirect treatment 
effect estimates for any of the treatment comparisons 
(supplementary table 2). None of the strategies was 
significantly less effective than “test and treat,” or more 
effective than each other, on either direct or indirect 
comparison (fig 3). Prompt endoscopy was ranked 
second, but performed similarly to “test and treat” 
(relative risk of remaining symptomatic 0.90, 95% 
confidence interval 0.80 to 1.02, P score 0.71). This 
means that the probability of “test and treat” or prompt 
endoscopy being the most effective strategy when all 
five management strategies, including symptom based 
management, were compared with each other was 
79% and 71%, respectively. In contrast, the probability 
of “test and scope,” empirical acid suppression, or 
symptom based management being the most effective 
strategy was 57%, 30%, and 12%, respectively.
Two of the trials of “test and treat” versus prompt 
endoscopy recruited only participants with H pylori 
infection,19 48 and one of the trials of prompt endoscopy 
versus empirical acid suppression used ranitidine,13 
rather than a proton pump inhibitor. Therefore, we 
excluded these three trials in a retrospective sensitivity 
analysis so as not to overestimate the effectiveness of 
“test and treat,” or underestimate the effectiveness of 
empirical acid suppression. When data were pooled, 
there was little observed heterogeneity (τ2=0.007). 
“Test and treat” was ranked first (relative risk 0.89, 
95% confidence interval 0.77 to 1.02, P score 0.82) 
and prompt endoscopy second (0.90, 0.79 to 1.02, 
P score 0.70). When we excluded the two trials of 
18 months’ duration, the overall results were not 
affected15 16; “test and treat” was still ranked first and 
prompt endoscopy second.
Per protocol analysis
All 15 randomised controlled trials provided dicho-
tomous data for likelihood of remaining symptomatic 
at the final point of follow-up according to a per 
protocol analysis.13-19 45 48-54 In this analysis, there 
were data on 5154 participants, of whom 1667 were 
randomised to prompt endoscopy, 326 to “test and 
scope,” 1689 to “test and treat,” 1150 to empirical 
acid suppression, and 322 to symptom based manage-
ment. Supplementary fig 7 presents the network 
plot. Again, when data were pooled, there was little 
observed heterogeneity (τ2=0.009), and no evidence 
of publication bias or other small study effects 
(supplementary fig 8). There were no red “hotspots” of 
inconsistency on the network heat plot (supplementary 
fig 9), with no evidence of inconsistency under the 
full design by treatment interaction model after 
applying the χ2 test of the Q statistic (1.28, P=0.97). 
The netsplit analysis did not identify any significant 
differences between the direct and indirect treatment 
effect estimates for any of the treatment comparisons 
(supplementary table 3). Once again, “test and treat” 
was ranked first (relative risk 0.87, 95% confidence 
interval 0.74 to 1.03, P score 0.79; supplementary 
fig 10), but was not superior to any of the other four 
strategies, and none of the strategies was more 
effective than any of the others on direct or indirect 
comparison (supplementary table 4). The P scores for 
prompt endoscopy, “test and scope,” empirical acid 
suppression, or symptom based management were 
0.69, 0.63, 0.26, and 0.13, respectively. As before, 
when we excluded the three aforementioned trials in 
a retrospective sensitivity analysis,13 19 48 there was 
little observed heterogeneity (τ2=0.007), and “test 
and treat” was ranked first (relative risk 0.87, 95% 
confidence interval 0.73 to 1.02, P score 0.81), with 
prompt endoscopy second (0.88, 0.76 to 1.03, P score 
0.68). Again, excluding the two trials of 18 months’ 
duration did not affect the overall results15 16; “test 
and treat” was still ranked first and prompt endoscopy 
second.
rates of endoscopy
Fourteen randomised controlled trials that comprised 
5897 participants, provided data on the number of 
participants in each arm undergoing endoscopy.13-19 45 
48-53 Supplementary fig 11 presents the network plot. 
When data were pooled, there was a moderate level 
of statistical heterogeneity (τ2=0.16), but no evidence 
of publication bias or other small study effects 
(supplementary fig 12). The network heat plot had no 
red “hotspots” of inconsistency (supplementary fig 
13), and there was no evidence of inconsistency under 
the full design by treatment interaction model after 
we applied the χ2 test of the Q statistic (2.56, P=0.63). 
The netsplit analysis did not identify any significant 
differences between the direct and indirect treatment 
effect estimates for any of the treatment comparisons 
(supplementary table 5). Of the five strategies, “test 
and treat” was ranked first (relative risk of receiving 
endoscopy 0.23, 95% confidence interval 0.17 to 
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0.31, P score 0.98; fig 4). When we performed an 
indirect comparison we found participants allocated to 
“test and treat” were significantly less likely to receive 
endoscopy than those in any of the other management 
strategies, except symptom based management. 
Participants assigned to all four other strategies were 
significantly less likely to receive endoscopy than those 
randomised to prompt endoscopy (fig 5). When we 
performed a direct comparison, we found participants 
randomised to “test and treat” or empirical acid 
suppression were significantly less likely to receive 
endoscopy than those assigned to prompt endoscopy.
Participant dissatisfaction with management
Only six trials that comprised 2818 participants 
reported rates of satisfaction with management 
according to strategy13 18 45 49-51; no randomised 
controlled trials reported on satisfaction with symp-
tom based management. Supplementary fig 14 
presents the network plot. The term “risk” has 
negative connotations; therefore, in this analysis, we 
chose to extract data as rates of dissatisfaction with 
management, such that the best performing strategy 
has the lowest risk of dissatisfaction (rather than the 
highest risk of being satisfied). When data were pooled, 
there was a moderate level of statistical heterogeneity 
(τ2=0.13), and too few randomised controlled trials to 
assess for evidence of publication bias, or other small 
study effects. Of the four strategies, prompt endoscopy 
was ranked first (relative risk of being dissatisfied 
0.58, 95% confidence interval 0.37 to 0.91, P score 
0.95; supplementary fig 15). Participants allocated 
to prompt endoscopy were significantly less likely 
to be dissatisfied with management compared with 
participants randomised to “test and treat” or empirical 
acid suppression, on indirect comparison, and with 
empirical acid suppression on direct comparison 
(supplementary table 6). The netsplit analysis did 
not identify any significant differences between the 
direct and indirect treatment effect estimates for any 
of the treatment comparisons (supplementary table 
7). However, the network heat plot revealed a red 
“hotspot” of potential inconsistency (supplementary 
fig 16), with evidence of inconsistency under the full 
design by treatment interaction model after applying 
the χ2 test of the Q statistic (26.07, P<0.001). This 
was driven by one early study of prompt endoscopy 
versus empirical acid suppression,13 which showed 
substantially higher rates of dissatisfaction with 
empirical acid suppression. Rerunning the network 
without this trial resolved the inconsistency (Q statistic 
1.73, P=0.42) and reduced heterogeneity (τ2=0.002), 
but did not change the ranking of prompt endoscopy 
(relative risk 0.85, 95% confidence interval 0.70 to 
1.02, P score 0.97).
Intervention
Prompt endoscopy
Empirical acid suppression
“Test and treat”
Symptom based management
“Test and scope”
Abbreviation
A
B
C
D
E
Number of
trial arms
11
7
10
3
2
Number of
participants
1942
1329
1938
469
484
B
C
D
E
A
fig 1 | network plot for likelihood of remaining symptomatic according to intention to 
treat analysis at final point of follow-up
“Test and treat”
Prompt endoscopy
“Test and scope”
Empirical acid suppression
0.7 0.9 1.11.0 1.2
Strategy
Favours
experimental
Favours symptom
based management
Relative risk
(95% CI)
0.89 (0.78 to 1.02)
0.90 (0.80 to 1.02)
0.92 (0.79 to 1.07)
0.96 (0.83 to 1.09)
Relative risk
(95% CI)
0.79
0.71
0.57
0.30
P score
fig 2 | forest plot for likelihood of remaining symptomatic according to intention to treat analysis at final point of 
follow-up. P score is probability of each treatment being ranked as best in network analysis. Higher score indicates 
greater probability of being ranked first
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rates of upper gastrointestinal cancer detection
Eleven randomised controlled trials reported upper 
gastrointestinal cancer detection rates among 5028 
participants.13-18 48-52 In total, 20 (0.40%) cancers 
were detected: 11 (0.67%) among 1644 participants 
undergoing prompt endoscopy; four (0.24%) among 
1672 participants allocated to “test and treat”; two 
(0.41%) among 484 participants assigned to “test 
and scope”; two (0.24%) among 849 participants 
randomised to empirical acid suppression; and one 
(0.26%) among 379 participants given symptom 
based management. Cancer location and type were 
provided for 16 participants; gastric adenocarcinoma 
occurred in 12 people, gastric lymphoma in two 
people, and oesophageal carcinoma in two people. 
Both participants with oesophageal carcinoma had 
previously reported dysphagia, and arguably, were 
recruited inappropriately to the relevant trial.18
discussion
Principal findings
This systematic review and network meta-analysis has 
shown that “test and treat” might be the most effective 
first line strategy for the management of uninvestigated 
dyspepsia in primary care, in terms of effect on 
symptoms, although prompt endoscopy performed 
similarly in this respect. However, no strategy was 
significantly less effective than “test and treat,” or 
more effective than another strategy, on either direct or 
indirect comparison. “Test and treat” was significantly 
more likely to reduce use of endoscopy compared with 
all strategies, other than symptom based management. 
Despite this, rates of dissatisfaction with management 
were significantly lower among participants allocated 
to prompt endoscopy compared with “test and treat” 
or empirical acid suppression on indirect comparison. 
Finally, detection rates of upper gastrointestinal cancer 
in these trials were extremely low.
strengths and limitations of the study
The network meta-analysis allowed us to make indirect 
comparisons among over 6000 participants in 15 
randomised controlled trials. The trials themselves 
were pragmatic and recruited participants from pri-
mary care, or on first referral to secondary care, 
which meant the results of our study are likely to be 
generalisable to other patients who present with 
dyspepsia in this setting. We used the most stringent 
endpoint for effect on symptoms in all trials, and 
only classified participants who were completely 
asymptomatic as having reached the endpoint of 
interest. We used an intention to treat analysis, with 
all trial dropouts assumed to be symptomatic. Because 
of the length of follow-up in individual randomised 
controlled trials, we performed a sensitivity analysis 
by using a per protocol analysis. We also excluded 
“Test and treat” 1.01 (0.93 to 1.10) 1.02 (0.81 to 1.28) 0.91 (0.82 to 1.01) NA
0.99 (0.92 to 1.07)
Prompt
endoscopy 0.94 (0.75 to 1.19) 0.96 (0.86 to 1.08) 0.90 (0.78 to 1.05)
0.97 (0.83 to 1.13) 0.98 (0.84 to 1.14) “Test and scope” 0.99 (0.79 to 1.25) 0.92 (0.76 to 1.11)
0.93 (0.86 to 1.01) 0.94 (0.87 to 1.03) 0.96 (0.82 to 1.12)
Empirical acid
suppression 0.93 (0.75 to 1.16)
0.89 (0.78 to 1.02) 0.90 (0.80 to 1.02) 0.92 (0.79 to 1.07) 0.96 (0.83 to 1.09)
Symptom based
management
fig 3 | summary treatment effects from network meta-analysis for likelihood of remaining symptomatic according to 
intention to treat analysis at final point of follow-up. comparisons, column versus row, should be read from left to 
right, and are ordered relative to overall effectiveness. treatment in top left position is ranked as best after network 
meta-analysis of direct and indirect effects. Direct comparisons are provided above strategy labels, and indirect 
comparisons are below. values are relative risk (95% confidence interval). na=not applicable, no randomised 
controlled trials making direct comparisons
“Test and treat”
Symptom based management
Empirical acid suppression
“Test and scope”
0.1 1.0
Strategy
Favours
experimental
Favours prompt
endoscopy
Relative risk
(95% CI)
0.23 (0.17 to 0.31)
0.39 (0.20 to 0.74)
0.39 (0.27 to 0.56)
0.55 (0.30 to 0.99)
Relative risk
(95% CI)
0.98
0.61
0.59
0.32
P score
fig 4 | forest plot for likelihood of receiving endoscopy. P score is probability of each treatment being ranked as best 
in network analysis. Higher score indicates greater probability of being ranked first
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two randomised controlled trials that examined 
effectiveness of prompt endoscopy versus “test 
and treat” only in participants who were H pylori 
positive19  48 and one that used empirical ranitidine 
as an acid suppressant13 in a separate retrospective 
sensitivity analysis. Our findings remained unchanged 
in this analysis. Finally, we produced network heat 
plots and identified inconsistency in one of our 
analyses, but this was resolved when we excluded one 
study that reported a large difference in dissatisfaction 
rates between prompt endoscopy and empirical acid 
suppression.
Our study had several limitations. We did not have 
access to individual patient data for the network 
meta-analysis, which meant that we were unable 
to study the effects of the various management 
strategies on other dyspepsia related resource use, or 
total costs of managing dyspepsia. There were also 
differences between individual trials in the population 
studied, study setting, the way the intervention was 
applied, duration of follow-up, and endpoint used 
to define symptom response; therefore, it might not 
be appropriate to combine data from these trials in 
a meta-analysis. However, we only classed those as 
entirely asymptomatic as having reached the endpoint 
of interest, and we performed sensitivity analyses 
based on some of these study characteristics, and 
our results were unchanged. These differences could 
explain the moderate amounts of heterogeneity in 
some of our analyses.
Additionally, only six randomised controlled trials 
contributed data to the analysis of dissatisfaction with 
management,13 18 45 49-51 and four of these compared 
prompt endoscopy with “test and treat,”18 49-51 which 
meant that the findings from this analysis might not be 
as robust for the other strategies. We were not able to 
examine the effect of these management strategies on 
quality of life in the network meta-analysis because the 
included studies used a variety of instruments, disease 
specific and generic; they also reported these analyses 
in a multitude of ways, which precluded pooling of the 
data. Because most studies were conducted in western 
populations, with only one randomised controlled 
trial conducted in Malaysia,51 our findings cannot 
be extrapolated to the Far East where the incidence 
of gastric cancer is higher, and prompt endoscopy 
might therefore be more appropriate. Finally, all of the 
included randomised controlled trials were at high risk 
of bias because of their pragmatic design, which meant 
that blinding of participants was not possible.
comparison with other studies
We believe this network meta-analysis is an advance 
over previous meta-analyses in this field for several 
reasons. Our meta-analysis produces a credible 
ranking system for each strategy, rather than relying 
on summary relative risks of comparative effectiveness 
of one strategy over another. This approach is clinically 
useful given that in previous individual patient data 
meta-analyses there was only a small, although 
statistically significant, difference in the relative risk 
of remaining symptomatic, which favoured prompt 
endoscopy over “test and treat.”19 Additionally, no 
difference was found between “test and treat” and 
empirical acid suppression.22 Furthermore, more 
randomised controlled trials have been included in 
our analysis than in the aforementioned individual 
patient data meta-analyses,19 22 and a previous trial 
based meta-analysis.55 Our meta-analysis was also 
able to make indirect and direct comparisons by using 
trial data, which led to a change in the strategy that 
could be the most effective for first line management 
of uninvestigated dyspepsia. “Test and treat” was 
ranked above prompt endoscopy, although P scores 
were similar. Additionally, the equipoise between 
“test and treat” and empirical acid suppression 
was no longer seen, with a P score for “test and 
treat” of 0.79 compared with 0.30 for empirical acid 
suppression. Although National Institute for Health 
and Care Excellence guidance states that either “test 
and treat” or empirical acid suppression can be used 
first line for uninvestigated dyspepsia,21 the “test 
and treat” strategy was recommended first line for 
patients younger than 60 by the more recent American 
College of Gastroenterology and Canadian Associa-
tion of Gastroenterology joint practice guideline on 
“Test and treat” NA 0.72 (0.47 to 1.09) 0.53 (0.23 to 1.21) 0.21 (0.15 to 0.29)
0.60 (0.30 to 1.18)
Symptom based
management NA 0.56 (0.24 to 1.27) 0.48 (0.22 to 1.08)
0.59 (0.42 to 0.84) 0.99 (0.49 to 2.01)
“Test and scope”
0.84 (0.37 to 1.90) 0.48 (0.31 to 0.76)
0.42 (0.23 to 0.78) 0.71 (0.37 to 1.35) 0.71 (0.38 to 1.33)
Empirical acid
suppression
0.51 (0.23 to 1.12)
0.23 (0.17 to 0.31) 0.39 (0.20 to 0.74) 0.39 (0.27 to 0.56) 0.55 (0.30 to 0.99)
Prompt
endoscopy
fig 5 | summary treatment effects from network meta-analysis for likelihood of receiving endoscopy. comparisons, 
column versus row, should be read from left to right, and are ordered relative to overall effectiveness. treatment in 
top left position is ranked as best after network meta-analysis of direct and indirect effects. Orange boxes indicate 
significant differences. Direct comparisons are provided above strategy labels, and indirect comparisons are below. 
values are relative risk (95% confidence interval). na=not applicable, no randomised controlled trials making direct 
comparisons
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dyspepsia.20 The results of our network meta-analysis 
support the latter recommendation. Finally, a previous 
trial based meta-analysis combined participants in 
the empirical acid suppression and symptom based 
management arms.55 Because those receiving symptom 
based management did not receive standardised proton 
pump inhibitor dosing in these randomised controlled 
trials, we believe this is technically incorrect, and 
might have led to an underestimate of the effectiveness 
of empirical acid suppression.
Dyspepsia, however defined, is a frequent reason 
for consultation with primary care providers and 
gastroenterologists. Dyspeptic symptoms can cause 
substantial anxiety for patients who might fear that 
they have a serious underlying condition to account 
for their symptoms. This anxiety is despite the fact 
that upper gastrointestinal malignancy is identified at 
endoscopy in less than 1% of patients.56 Of note, the 
rate of upper gastrointestinal malignancy in this meta-
analysis was only around 0.4%, which suggests that, 
among 1000 patients presenting to a primary care 
provider with uninvestigated dyspepsia, 996 would be 
cancer free on endoscopy. This makes the strategy of 
prompt endoscopy for the evaluation of uninvestigated 
dyspepsia highly questionable, at least in the absence 
of potentially important alarm features that, arguably, 
would merit endoscopy in any case. A previous study 
in the USA estimated that the cost of detecting one 
upper gastrointestinal cancer in patients aged 50 
or older with dyspepsia without alarm features in 
primary care was over $80 000 (£62 000; €72 300).57 
Prompt endoscopy might be justifiable on the basis of 
providing reassurance to patients about the absence 
of a sinister underlying cause of their symptoms, but 
studies suggest this effect is relatively short lived.58 
Although “test and treat” was ranked first in terms 
of effectiveness, and significantly limited the use of 
endoscopy, we found lower levels of dissatisfaction 
with management among participants randomised to 
prompt endoscopy. Given the lack of blinding in all 
of the included studies, this could relate to patients’ 
previous expectations of management, which were 
not met if assigned to a non-invasive management 
strategy; patients might prefer endoscopy for what 
they consider to be a more thorough and appropriate 
evaluation of their symptoms. Furthermore, the impact 
of negative findings at endoscopy probably also 
influences patients’ satisfaction with this approach.
We must weigh these potential benefits of endoscopy 
against its substantial costs and the risk of adverse 
events, albeit small. Because endoscopy is the principal 
driver of overall costs in the management of dyspepsia, 
it cannot be supported based on cost effectiveness. This 
consideration is underlined by a previous individual 
patient data meta-analysis of prompt endoscopy 
versus “test and treat,”19 which estimated that prompt 
endoscopy was only cost effective if the willingness to 
pay per patient cured of their dyspepsia was $180 000. 
Endoscopy can identify H pylori infection, although 
it is not essential for that purpose because there are 
widely available, cheaper, non-invasive tests for active 
infection with excellent performance characteristics. 
However, the American Gastroenterological Associa-
tion has recommended routine collection of gastric 
biopsies at endoscopy when performed in patients 
with dyspepsia to document the presence or absence 
of H pylori infection59; however, treatment of the 
infection leads to sustained symptom improvement in 
only a minority of patients.60
conclusions and policy implications
The strategy of “test and treat” has proved popular 
in many countries. H pylori infection is usually 
asymptomatic, but it can lead to dyspepsia even in the 
absence of peptic ulcer disease.61 The non-invasive 
detection of H pylori infection with a reliable test, such 
as the urea breath test or faecal antigen test, should 
lead automatically to treatment for the infection. The 
“test and treat” strategy would detect most patients 
with dyspepsia and underlying peptic ulcer disease, 
although it would not identify them individually; 
they would certainly benefit from eradication of 
the infection. However, most patients with H pylori 
infection would not have peptic ulcer disease and 
many would fulfil diagnostic criteria for functional 
dyspepsia. Eradication of the infection would produce 
sustained improvement in only a minority of these 
patients, but it would remove a potentially serious 
cause of disease in the remainder. Population screening 
and treatment for H pylori appears to reduce future 
dyspepsia related costs in the West,62 and also reduces 
incidence of gastric cancer in high risk populations,63 
so there are probably other benefits from more 
widespread use of “test and treat.” That said, many of 
the trials included in the network meta-analysis were 
conducted more than 15 years ago, and the prevalence 
of H pylori infection might have declined in Western 
populations during this time. A simulation model of 
the cost effectiveness of management strategies for 
uninvestigated dyspepsia in the USA suggested that 
“test and treat” was unlikely to remain cost effective 
below a prevalence of infection of 20%, although the 
confidence intervals were wide.64
Symptom based management was ranked the lowest 
of all the strategies when considering effectiveness. 
Management of dyspepsia with drug treatments is 
unsatisfactory and often lacks an adequate evidence 
base because the underlying causes of symptoms 
are poorly understood. This makes targeted drug 
interventions empirical at best. Patients with dyspepsia 
might be treated with a variety of drugs, depending on 
local availability and approval, physicians’ personal 
experience, and to some extent, on assessment of 
an individual patient’s symptom profile. Recent 
guidelines recommend the use of empirical proton 
pump inhibitor treatment for patients younger than 
60 in whom “test and treat” is unsuccessful and in 
those without H pylori infection.20 Although acid 
suppression with a proton pump inhibitor might be 
effective for some patients,65 their long term efficacy is 
unclear and the optimal duration of treatment is not 
defined. In patients whose dyspeptic symptoms do not 
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respond to a proton pump inhibitor, there is no value 
in continuing with this treatment. Furthermore, recent 
concerns about the long term safety of these drugs, 
although often based on weak evidence,66 could have 
altered perceptions of their appropriateness for the 
long term management of dyspepsia. Additional drug 
interventions that could be used for the management 
of dyspepsia include drugs with presumed prokinetic 
effects67 and neuromodulators, including tricyclic 
antidepressants.68 The role of prokinetic agents is 
limited because of their lack of availability in many 
countries. Neuromodulators have an important role 
in the management of dyspepsia and other functional 
gastrointestinal disorders.68-70 However, the decision 
to use any of these drugs, and the order in which 
they might be tried, is based on choices made by 
individual physicians and patients, and to some extent 
is influenced by the factors listed here. Therefore, it 
is perhaps unsurprising that this largely empirical 
strategy was the least effective.
In summary, dyspepsia continues to be a highly 
prevalent condition that can influence quality of 
life profoundly and accounts for major healthcare 
expenditures. Many different management strategies 
have been studied in individual randomised controlled 
trials. This network meta-analysis provides additional 
support for the so called “test and treat” approach in 
management. This strategy, recently recommended 
in national guidelines,20 was consistently associated 
with the lowest chance of remaining symptomatic 
and with the lowest use of endoscopy. Therefore, it is 
probably of benefit in reducing overall costs, at least 
in some healthcare delivery models. However, despite 
the low diagnostic yield of endoscopy in detecting 
upper gastrointestinal tract malignancy, it might be 
the strategy most preferred by patients. Management 
of patients with dyspepsia should continue to be based 
on best evidence, but should also take into account the 
nuances of the individual patient within the confines 
of the healthcare setting.
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